Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | STE/STE20/MSN protein kinase | 0.0181 | 0.3629 | 0.586 |
Echinococcus granulosus | mitogen activated protein kinase 11 | 0.0247 | 0.5907 | 0.5907 |
Trypanosoma cruzi | mitogen-activated protein kinase 3, putative | 0.0247 | 0.5907 | 0.5 |
Trypanosoma brucei | mitogen-activated protein kinase 3, putative | 0.0247 | 0.5907 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase 14 | 0.0247 | 0.5907 | 0.5907 |
Loa Loa (eye worm) | hypothetical protein | 0.0255 | 0.6192 | 1 |
Echinococcus granulosus | protein kinase | 0.0181 | 0.3629 | 0.3629 |
Schistosoma mansoni | protein kinase | 0.0257 | 0.6256 | 1 |
Echinococcus multilocularis | tumor protein p63 | 0.0364 | 1 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase 11 | 0.0247 | 0.5907 | 0.5907 |
Echinococcus granulosus | serine:threonine protein kinase mig 15 | 0.0255 | 0.6192 | 0.6192 |
Loa Loa (eye worm) | CMGC/MAPK/P38 protein kinase | 0.0247 | 0.5907 | 0.9539 |
Echinococcus multilocularis | mitogen activated protein kinase 14 | 0.0247 | 0.5907 | 0.5907 |
Brugia malayi | probable protein kinase | 0.0257 | 0.6256 | 1 |
Echinococcus multilocularis | 0.0181 | 0.3629 | 0.3629 | |
Brugia malayi | P38 map kinase family protein 2 | 0.0247 | 0.5907 | 0.9442 |
Schistosoma mansoni | protein kinase | 0.0181 | 0.3629 | 0.5801 |
Leishmania major | mitogen-activated protein kinase 3, putative,map kinase 3, putative | 0.0247 | 0.5907 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 11 | 0.0247 | 0.5907 | 0.5907 |
Trypanosoma cruzi | mitogen-activated protein kinase 3, putative | 0.0247 | 0.5907 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 14 | 0.0247 | 0.5907 | 0.5907 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.